Patents by Inventor James N. KOCHENDERFER

James N. KOCHENDERFER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240165153
    Abstract: An aspect of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: March 23, 2022
    Publication date: May 23, 2024
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: James N. Kochenderfer, Norris Lam
  • Patent number: 11951131
    Abstract: Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 9, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: James N. Kochenderfer, Steven A. Feldman
  • Publication number: 20240091264
    Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: November 30, 2023
    Publication date: March 21, 2024
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, TeneoBio, Inc.
    Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
  • Publication number: 20240082307
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
    Type: Application
    Filed: August 24, 2023
    Publication date: March 14, 2024
    Applicants: Kite Pharma, Inc., Ofc of Tech Transfer, NIH
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • Patent number: 11827889
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: November 28, 2023
    Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 11779601
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 10, 2023
    Assignees: Kite Pharma, Inc., The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Patent number: 11773396
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: October 3, 2023
    Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20230158075
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: September 27, 2022
    Publication date: May 25, 2023
    Applicants: Kite Pharma Inc., United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • Publication number: 20230050416
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: October 6, 2022
    Publication date: February 16, 2023
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20230030998
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: October 6, 2022
    Publication date: February 2, 2023
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20230002776
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: May 16, 2022
    Publication date: January 5, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 11491187
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: November 8, 2022
    Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Patent number: 11377660
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: July 5, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20220204619
    Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 30, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 11359204
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: June 14, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20220153838
    Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
    Type: Application
    Filed: December 21, 2021
    Publication date: May 19, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 11236161
    Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: February 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20210363245
    Abstract: An embodiment of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: September 17, 2019
    Publication date: November 25, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: James N. Kochenderfer, Shicheng Yang
  • Publication number: 20210260125
    Abstract: Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: June 26, 2019
    Publication date: August 26, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: James N. Kochenderfer, Steven A. Feldman
  • Patent number: 11066674
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: July 20, 2021
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer